Daiichi Sankyo Korea Signs Agreement with Daewoong Pharmaceutical for the Co-promotion of LIXIANA in South Korea

1 min read

The FINANCIAL — Daiichi Sankyo Company, Limited on December 28 announced that its wholly owned subsidiary, Daiichi Sankyo Korea Co., Ltd. , and Daewoong Pharmaceutical Co., Ltd.  have signed an agreement for the co-promotion of the oral, once-daily anti-coagulant, LIXIANA.

Daewoong Pharmaceutical is also the co-promotion partner in South Korea for the Daiichi Sankyo antihypertensives Olmetec, Olmetec Plus, Sevikar, Sevikar HCT, and through this new agreement, Daiichi Sankyo Korea aims to maximize LIXIANA’s product value and further contribute to disease treatment and prevention in South Korea, according to Daiichi Sankyo.

LIXIANA was approved in South Korea in August 2015 and will be launched within this fiscal year.

 

Leave a Reply